Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORIC-101 · 2 trials · 1 indication
PK of ORIC-101 as single doses
PK of ORIC-101 as single doses
Safety and tolerability of ORIC-101 as single doses
Safety and tolerability of ORIC-101 as single doses
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | - |
| Regimen B | EXPERIMENTAL | - |
| Regimen C | EXPERIMENTAL | - |
| Regimen D | EXPERIMENTAL | - |
| Regimen F | EXPERIMENTAL | - |
| Regimen H | EXPERIMENTAL | - |
| Regimen I | EXPERIMENTAL | - |
| ORIC-101 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ORIC-101 | DRUG | Capsule or oral suspension |
Inclusion Criteria: * Healthy males or healthy females of non-child bearing potential * Age 18 to 65 years of age * Body mass index of 18.0 to 32.0 kg/m\^2 and weight between 50 kg and 120 kg, inclusive Exclusion Criteria: * Subjects who have received any investigational medicinal product (IMP) i...
ORIC-101 is an investigational small molecule developed by Oric Pharmaceuticals, Inc. It has been studied in Phase 1 clinical trials involving healthy adult volunteers. The specific disease indications being pursued for ORIC-101 have not been publicly disclosed, and the compound remains in early-stage clinical development.
ORIC-101 is being developed by Oric Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ORIC. The company sponsored both Phase 1 trials of the compound conducted to date.
ORIC-101 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
ORIC-101 has been evaluated in two completed Phase 1 trials. NCT03835637 was a single and multiple dose study in 32 adult healthy subjects in the United Kingdom. NCT03324555 was a study in 24 healthy adult subjects in the United States. Together these trials enrolled 56 participants.
The two completed Phase 1 trials of ORIC-101 were controlled studies but were not randomized and not double blinded. Both trials enrolled healthy adult volunteers, with 32 participants in NCT03835637 and 24 participants in NCT03324555, for a total enrollment of 56.